IPO Timeline
Broker Results (T-2)
2021-02-02
Some brokers release in afternoon
Grey Market (T-1)
2021-02-03
Afternoon
HKEX Allotment (T-1)
2021-02-03
Evening
Registrar Allotment (T-1)
2021-02-03
Evening
Listing Day (T)
2021-02-04
First day of trading
Company Overview
| Stock Name | 微創心通醫療科技有限公司 - B |
|---|---|
| Stock Code | 02160 |
| Company Full Name | 微創心通醫療科技有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事研發、制造及銷售用於治療心臟瓣膜疾病的醫療器械。 |
| Listing Date | 2021-02-04 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張江高科技園區張東路1601號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.cardioflowmedtech.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 12.20 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 38.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,254,282,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 18.82 |
|---|---|
| First Day Open | HK$ 21.5 |
| First Day Change | 54.26% |
| First Day Volume | 186931000.0 |
| First Day Turnover | 3780700000.0 |
Use of Proceeds
| Use of Proceeds | 1、30.0%（或約706.8百萬港元）將被分配予我們的核心產品（即VitaFlowTMII）； 2、3.4%（或約80.1百萬港元）將被分配予我們首款商業化TAVI產品（即VitaFlowTM）； 3、27.0%（或約636.1百萬港元）將被分配予我們目前產品管線的其他產品； 4、15.0%（或約353.4百萬港元）將獲分配用于為通過并購、授權引進或股權投資等方式與包括醫療器械企業及研究機構在內的全球賦能者合作擴展我們的產品組合提供資金； 5、14.6%（或約344.0百萬港元）將用于擴大我們的產能并提高我們生產VitaFlowTM及VitaFlowTMII的能力； 6、10.0%（或約235.6百萬港元）將用作我們的營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
J.P. Morgan Securities (Far East) Limited CE AAB026
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (3)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (3)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (3)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 2 | CDG Group Fund L.P. | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 3 | CPE Greater China Enterprises Growth Fund | 155,062,000 HKD | — | 6.20% | — | 6 months | 2021-08-04 |
| 4 | GIC Private Limited | 77,531,000 HKD | — | 3.10% | — | 6 months | 2021-08-04 |
| 5 | Hillhouse Funds | 116,302,600 HKD | — | 4.60% | — | 6 months | 2021-08-04 |
| 6 | Indus Funds | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 7 | Lake Bleu Prime Healthcare Master Fund Limited | 77,531,000 HKD | — | 3.10% | — | 6 months | 2021-08-04 |
| 8 | Snow Lake China Master Fund, Ltd. | 77,531,000 HKD | — | 3.10% | — | 6 months | 2021-08-04 |
| 9 | Tybourne Funds | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 10 | Woodline Master Fund LP | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 11 | WT China Focus Fund | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 12 | Yi Fang Da Brocade Inv. Limited | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 13 | 保银资产管理有限公司 | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 14 | 华夏基金管理有限公司 | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 15 | 昆仑集团有限公司 | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 16 | 泰康人寿保险有限责任公司 | 77,531,000 HKD | — | 3.10% | — | 6 months | 2021-08-04 |
Directors & Management
| Chairman | 陳國明 |
|---|---|
| Company Secretary | 李香梅;陳濼而 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 微創醫療科學有限公司(46.25%);中金康瑞壹期(寧波)股權投資基金合伙企業(7.55%);上海鏵浩企業管理合伙企業(有限合伙)(5.99%) |
|---|
IPO Timeline
